Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top

Targeted Oncology

Issue 2/2011

Content (7 Articles)

Editorial

Are we ready to move away from nature? The rapamycin story

Monica Mita, Alain Mita

Original Research

Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges

Laura Catena, Emilio Bajetta, Massimo Milione, Monika Ducceschi, Monica Valente, Francesca Dominoni, Valentina Colonna

Review

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

Yesid Alvarado, Monica M. Mita, Sushma Vemulapalli, Devalingam Mahalingam, Alain C. Mita

Review

Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences

Hakan Cam, Peter J. Houghton

Review

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs

Shin Ogita, Patricia LoRusso

Review

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

Catherine Delbaldo, Sébastien Albert, Chantal Dreyer, Marie-Paule Sablin, Maria Serova, Eric Raymond, Sandrine Faivre

Review

Common toxicities of mammalian target of rapamycin inhibitors

Scott A. Soefje, Anand Karnad, Andrew J. Brenner

Mar 11
Issue: 1/2011
Sep 11
Issue: 3/2011

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits